Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh CellsAlexander Roesch, Meenhard Herlyn, Adina Vultur et al.|Cancer Cell|2013Cited by 680
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialGeorgina V. Long, Paolo A. Ascierto, Charles H. Yoon et al.|The Lancet Oncology|2022Cited by 149
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 StudyJason J. Luke, Georgina V. Long, Paolo A. Ascierto et al.|Journal of Clinical Oncology|2024Cited by 106
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyMuhammad A. Khattak, John M. Kirkwood, Jason J. Luke et al.|European Journal of Cancer|2022Cited by 22
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.Jason J. Luke, Georgina V. Long, Paolo A. Ascierto et al.|Journal of Clinical Oncology|2023Cited by 18